ABL2, a member of the Abelson family of non-receptor tyrosine kinases, was identified as target of miR-142-5p in the present study and is known to be upregulated in CML disease progression [21–23]. This evidence concerns the gene ABL2 and chronic myelogenous leukemia, BCR-ABL1 positive.